发布求助
文献互助 智能选刊 最新文献

Current Opinion in Pharmacology最新文献

筛选
英文 中文
Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence 所有可切除胰腺导管腺癌患者的常规新辅助化疗?证据的回顾
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102305
Zachary J. Brown, Samantha M. Ruff, Jordan M. Cloyd
{"title":"Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence","authors":"Zachary J. Brown,&nbsp;Samantha M. Ruff,&nbsp;Jordan M. Cloyd","doi":"10.1016/j.coph.2022.102305","DOIUrl":"10.1016/j.coph.2022.102305","url":null,"abstract":"<div><p>Pancreatic ductal adenocarcinoma<span> is an aggressive malignancy that carries a poor prognosis because the majority of patients present with locally advanced or metastatic disease. However, even patients who are fortunate enough to present with resectable disease are often plagued by high recurrence rates. While adjuvant chemotherapy has been shown to decrease the risk of recurrence after surgery, post operative complications and poor performance status after surgery prevent up to 50% of patients from receiving it. Given the benefits of neoadjuvant therapy in patients with borderline resectable disease, it is understandable that neoadjuvant therapy has been steadily increasing in patients with resectable cancers as well. In this review paper, we highlight the rational and existing evidence of using neoadjuvant therapy in all patients with resectable pancreatic adenocarcinoma.</span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102305"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9121789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting KNDy neurons to control GnRH pulses 靶向KNDy神经元控制GnRH脉冲
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102316
Stephanie Constantin
{"title":"Targeting KNDy neurons to control GnRH pulses","authors":"Stephanie Constantin","doi":"10.1016/j.coph.2022.102316","DOIUrl":"10.1016/j.coph.2022.102316","url":null,"abstract":"<div><p><span><span>Gonadotropin-releasing hormone (GnRH) is the final output of the central nervous system<span> that drives fertility. A characteristic of GnRH secretion is its pulsatility, which is driven by a pulse generator. Each GnRH pulse triggers a luteinizing hormone (LH) pulse. However, the puzzle has been to reconcile the synchronicity of GnRH neurons with the scattered hypothalamic distribution of their cell bodies. A leap toward understanding GnRH pulses was the discovery of </span></span>kisspeptin<span> neurons near the distal processes of GnRH neurons, which secrete kisspeptins, potent excitatory neuropeptides<span> on GnRH neurons, and equipped with dual, but opposite, self-modulatory neuropeptides, neurokinin B and </span></span></span>dynorphin. Over the last decade, this cell-to-cell communication has been dissected in animal models. Today the 50-year quest for the basic mechanism of GnRH pulse generation may be over, but questions about its physiological tuning remain. Here is an overview of recent basic research that frames translational research.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102316"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10576462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The emerging role of immunotherapy in the treatment of anal cancer 免疫疗法在肛门癌治疗中的新作用
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102309
Rita Saúde-Conde , Alessandro Parisi , Emilio Francesco Giunta , Michel Meyers , Francesco Sclafani
{"title":"The emerging role of immunotherapy in the treatment of anal cancer","authors":"Rita Saúde-Conde ,&nbsp;Alessandro Parisi ,&nbsp;Emilio Francesco Giunta ,&nbsp;Michel Meyers ,&nbsp;Francesco Sclafani","doi":"10.1016/j.coph.2022.102309","DOIUrl":"10.1016/j.coph.2022.102309","url":null,"abstract":"<div><p>For decades, chemoradiotherapy<span><span> for early-stage disease and systemic chemotherapy for advanced disease have represented the mainstay of treatment for anal cancer. Over the last few years, however, the advent of </span>immunotherapy<span> has opened interesting therapeutic perspectives, with the establishment of new standards of care, and the development of clinical trials that may further shape the treatment algorithm for this tumour. In this review article, we discuss the rationale behind the use of immunotherapy for anal cancer and provide an overview of the available clinical data and ongoing efforts to build on these.</span></span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102309"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10571555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Systemic inflammation after spinal cord injury: A review of biological evidence, related health risks, and potential therapies 脊髓损伤后全身性炎症:生物学证据、相关健康风险和潜在治疗方法综述
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102303
Gregory E. Bigford , Eric Garshick
{"title":"Systemic inflammation after spinal cord injury: A review of biological evidence, related health risks, and potential therapies","authors":"Gregory E. Bigford ,&nbsp;Eric Garshick","doi":"10.1016/j.coph.2022.102303","DOIUrl":"10.1016/j.coph.2022.102303","url":null,"abstract":"<div><p>Individuals with chronic traumatic spinal cord injury (SCI) develop progressive multi-system health problems that result in clinical illness and disability. Systemic inflammation is associated with many of the common medical complications and acquired diseases that accompany chronic SCI, suggesting that it contributes to a number of comorbid pathological conditions. However, many of the mechanisms that promote persistent systemic inflammation and its consequences remain ill-defined. This review describes the significant biological factors that contribute to systemic inflammation, major organ systems affected, health risks, and the potential treatment strategies. We aim to highlight the need for a better understanding of inflammatory processes, and to establish appropriate strategies to address inflammation in SCI.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102303"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10734637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Reprogramming cell fates towards novel cancer immunotherapies 重新编程细胞命运以实现新的癌症免疫疗法
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102312
Eva Hin Wa Leung , Kenneth Joves , Aydolun Petenkaya , Georgina Barham , Thomas G. Henderson , Jie Liang , Constantinos Chronis
{"title":"Reprogramming cell fates towards novel cancer immunotherapies","authors":"Eva Hin Wa Leung ,&nbsp;Kenneth Joves ,&nbsp;Aydolun Petenkaya ,&nbsp;Georgina Barham ,&nbsp;Thomas G. Henderson ,&nbsp;Jie Liang ,&nbsp;Constantinos Chronis","doi":"10.1016/j.coph.2022.102312","DOIUrl":"10.1016/j.coph.2022.102312","url":null,"abstract":"<div><p>Recent advances in our understanding of host immune and cancer cells interactions have made immunotherapy a prominent choice in cancer treatment. Despite such promise, cell-based immunotherapies remain inapplicable to many patients due to severe limitations in the availability and quality of immune cells isolated from donors. Reprogramming technologies that facilitate the engineering of cell types of interest, are emerging as a putative solution to such challenges. Here we focus on the recent progress being made in reprogramming technologies with respect to the immune system and their potential for clinical applications.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102312"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10570111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stress, kisspeptin, and functional hypothalamic amenorrhea 应激、kisspeptin与功能性下丘脑闭经
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102288
Blazej Meczekalski , Olga Niwczyk , Gregory Bala , Anna Szeliga
{"title":"Stress, kisspeptin, and functional hypothalamic amenorrhea","authors":"Blazej Meczekalski ,&nbsp;Olga Niwczyk ,&nbsp;Gregory Bala ,&nbsp;Anna Szeliga","doi":"10.1016/j.coph.2022.102288","DOIUrl":"10.1016/j.coph.2022.102288","url":null,"abstract":"<div><p>Functional hypothalamic amenorrhea (FHA) is the most common cause of secondary amenorrhea in women of reproductive age. FHA is predominantly caused by stress, decreased caloric intake, excessive exercise, or a combination thereof. These physical, psychological, and metabolic stressors cause aberration in the pulsatile release of gonadotropin-releasing hormone (GnRH) and subsequently impair function of the hypothalamic–pituitary–ovarian (HPO) axis. Various neurotransmitters acting in the central nervous system are involved in control of the HPO axis and of these, kisspeptin is one of the most important. Corticotropin-releasing hormone (CRH), also inhibits the pulsatile secretion of GnRH and also acts as an intermediary between stress factors and the reproductive system. One of the main ongoing concerns in patients with FHA is chronic hypoestrogenism, a condition, which is associated with sexual dysfunction and infertility. It may also lead to osteoporosis, and predispose to neurodegenerative and cardiovascular diseases.</p><p>Treatment of FHA requires the elimination of causative factors, however, making the necessary lifestyle changes is not always easy to initiate and maintain. Broadening our knowledge of the complex neural mechanisms regulating reproductive function in which kisspeptin plays a key role can help in the development of new treatment options such as the potential of kisspeptin receptor agonists for patients with FHA.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102288"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1471489222001151/pdfft?md5=6a1e8fe36d26aca7c8b04db1c96da9e5&pid=1-s2.0-S1471489222001151-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10625779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Anabolic–androgenic steroid abuse and testicular function in men; recent insights 男性合成代谢雄激素类固醇滥用与睾丸功能的关系最近的见解
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102318
Willem de Ronde , Diederik L. Smit
{"title":"Anabolic–androgenic steroid abuse and testicular function in men; recent insights","authors":"Willem de Ronde ,&nbsp;Diederik L. Smit","doi":"10.1016/j.coph.2022.102318","DOIUrl":"10.1016/j.coph.2022.102318","url":null,"abstract":"<div><p>The use of illegal androgens by young men is not uncommon. The majority of users take multiple courses of androgens during their lifetime, leading to a high cumulative exposure. An inseparable side effect is suppression of gonadal function. Although this usually recovers, recovery can take a long time and is not without symptoms.</p><p>This review focusses on recent studies that have greatly increased our knowledge of the disruption and recovery of testicular function during and after androgen abuse. For the guidance and treatment of (potential) users, in-depth knowledge of this is indispensable.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102318"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10627367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Hormonal drugs for the treatment of endometriosis 治疗子宫内膜异位症的激素药物
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102311
Tommaso Capezzuoli, Margherita Rossi, Francesco La Torre, Silvia Vannuccini, Felice Petraglia
{"title":"Hormonal drugs for the treatment of endometriosis","authors":"Tommaso Capezzuoli,&nbsp;Margherita Rossi,&nbsp;Francesco La Torre,&nbsp;Silvia Vannuccini,&nbsp;Felice Petraglia","doi":"10.1016/j.coph.2022.102311","DOIUrl":"10.1016/j.coph.2022.102311","url":null,"abstract":"<div><p>In the past, the primary approach for the treatment of endometriosis was represented by surgery; however, after the introduction of non-invasive diagnosis of endometriosis with the development of imaging technologies, medical treatment became the preferred approach, particularly in young patients. Hormonal drugs, by blocking menstruation, are the most effective for the treatment of endometriosis-related pain, independently of phenotype (ovarian, deep, or superficial endometriosis).</p><p>Gonadotropin-releasing hormone analogs and oral antagonists act on hypothalamus-pituitary-ovary axis inducing iatrogenic menopause, thus reducing dysmenorrhea<span> and all pain symptoms. The side effects, such as hot flushes and bone loss, may be reduced by an add-back therapy. However, the cost in terms of women's health remains high in view of a long-term treatment.</span></p><p><span>Progestins are considered the first-line treatment, highly effective, and with reduced side effects. In addition to the well-known and largely used </span>Norethisterone acetate<span><span> and Medroxyprogesterone acetate, recently </span>Dienogest<span> has become one of the most used drugs in all endometriosis phenotypes for long-term treatment. Besides, Intrauterine levornogestrel or subcutaneous etonogestrel are valid alternative for long-term treatment.</span></span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102311"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10565067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis 银屑病和银屑病关节炎当前和新兴的生物和小分子系统治疗方案
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102292
Christine P. Lin , Joseph F. Merola , Elizabeth B. Wallace
{"title":"Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis","authors":"Christine P. Lin ,&nbsp;Joseph F. Merola ,&nbsp;Elizabeth B. Wallace","doi":"10.1016/j.coph.2022.102292","DOIUrl":"10.1016/j.coph.2022.102292","url":null,"abstract":"<div><p><span>Psoriasis and </span>psoriatic arthritis<span> are chronic inflammatory diseases<span> affecting the skin and joints, respectively. Psoriasis and psoriatic arthritis are associated with a high comorbidity burden as well as negative impact on quality of life. Impact on health-related quality of life is optimized when both skin and joint manifestations are effectively treated. The identification of key cytokines involved in disease pathogenesis has led to the development of several therapeutic options for psoriatic disease. When selecting a therapy, it is important to consider disease severity, psoriasis disease subtypes or domains of psoriatic arthritis, comorbidities, patient preference for treatment, among other factors. This review summarizes current biologic and small molecule treatment options as well as emerging therapies for moderate-to-severe adult plaque psoriasis and psoriatic arthritis.</span></span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102292"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10569691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials 轴性脊柱炎的当前治疗和分子靶点:来自随机对照试验的证据
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2022-12-01 DOI: 10.1016/j.coph.2022.102307
Rouhin Sen , Liron Caplan
{"title":"Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials","authors":"Rouhin Sen ,&nbsp;Liron Caplan","doi":"10.1016/j.coph.2022.102307","DOIUrl":"10.1016/j.coph.2022.102307","url":null,"abstract":"<div><p><span><span>Axial spondyloarthritis (axSpA) is a chronic </span>inflammatory disease<span> that predominantly affects the axial skeleton and is characterized by inflammatory </span></span>back pain<span>. While much has been published regarding non-steroidal anti-inflammatory drugs and tumor necrosis factor<span><span> inhibitors, other classes of medications which leverage alternate molecular mechanisms receive less attention. In this review, we summarize a few of the novel targets in axSpA, review the putative mechanism of action of therapies that focus on these targets, and reference the germane recently completed, ongoing, or proposed randomized controlled clinical trials<span>. The agents addressed include inhibitors of interleukin-23, interleukin-17, janus kinases<span>, granulocyte-macrophage colony-stimulating factor, macrophage migration inhibitory factor, antibodies recognizing </span></span></span>T cell receptor beta variable 9 gene positive clones, as well as inhibitors of mitogen-activated protein kinase-activated protein kinase-2.</span></span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"67 ","pages":"Article 102307"},"PeriodicalIF":4.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10570108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信